Temporal trend of circulating trans-fatty acids and risk of long-term mortality in general population
Participants receive multiple doses over a defined period for example, twice daily for seven days again following a cautious dose-escalation approach supported by continuous safety review
retatrutide adds a dose-dependent heart-rate signal and the highest adverse-event burden in indirect analyses
Calling it a peptide is wrong, though nearly every vendor does
A phase 3 trial of a higher-dose CagriSema formulation at 2.4/7.2 mg is planned for initiation in the second half of 2026, and the REDEFINE 11 trial, exploring CagriSemas full weight-loss potential, is expected to report data in the first half of 2027
This effect could be counteracted by MOR blockade which enhances the inhibition of DA neurons (decreases DA release), particularly in the VTA with higher MOR-expressing GABAergic interneurons than SNc [58]